Briefly Bio

Briefly Bio is a London-based software company that develops artificial intelligence platforms to capture, standardize, and share laboratory protocols for biological experiments. The platform automatically converts raw text into structured formats, identifies missing experimental details, and provides a collaborative workspace for wet-lab scientists and automation engineers across academia and the biotechnology industry. The software addresses the scientific reproducibility crisis, a systemic issue where over 50 percent of preclinical experiments fail to reproduce, causing an estimated $50 billion in annual industry losses. To support its platform commercialization and growth, Briefly Bio has raised $1.2 million in pre-seed funding backed by lead investor Compound, alongside participation from NP Hard and Tiny VC. The organization was founded in 2022 by Harrison Rickerby, Staffan Piledahl, and Katya Putintseva, who previously collaborated on machine learning-driven antibody discovery at LabGenius.